Finally, in a phase Ib study of patients with metastatic melanoma, the association between pembrolizumab (200 mg IV every 3 weeks) and escalating doses of IL-2 (6000 or 60,000 or 600,000 IU/kg IV bolus every 8 h up to 14 doses per cycle) was evaluated in cohorts of three patients. This evidence concerns the gene IL2 and metastatic melanoma.